|
2023 3 31 |
LT |
Europos Sąjungos oficialusis leidinys |
C 118/1 |
Europos Sąjungos sprendimų dėl vaistų rinkodaros leidimų santrauka nuo 2023 m. vasario 1 d. iki 2023 m. vasario 28 d.
(Paskelbta pagal Europos Parlamento ir Tarybos reglamento (EB) Nr. 726/2004 (1) 13 straipsnį arba 38 straipsnį arba Europos Parlamento ir Tarybos reglamento (ES) 2019/6 5 straipsnį (2))
(2023/C 118/01)
— Rinkodaros leidimo suteikimas (Europos Parlamento ir Tarybos reglamento (EB) Nr. 726/2004 13 straipsnis): Priimta
|
Sprendimo data |
Vaisto pavadinimas |
INN (Tarptautinis nepatentuotas pavadinimas) |
Rinkodaros leidimo turėtojas |
Įrašo numeris Bendrijos vaistų registre |
Farmacinė forma |
ATC kodas (Anatominis terapinis cheminis kodas) |
Pranešimo data |
||
|
2023 2 15 |
Dimethyl Fumarate Accord |
dimetilfumarato |
|
EU/1/22/1711 |
Skrandyje neirios kapsulės, kietos |
L04AX07 |
2023 2 17 |
||
|
2023 2 20 |
Hemgenix |
etranakogenas dezaparvovekas |
|
EU/1/22/1715 |
Koncentratas infuziniam tirpalui |
B06 |
2023 2 23 |
||
|
2023 2 20 |
IMJUDO |
tremelimumabas |
|
EU/1/22/1713 |
Koncentratas infuziniam tirpalui |
L01FX20 |
2023 2 23 |
||
|
2023 2 20 |
Tremelimumab AstraZeneca |
tremelimumabas |
|
EU/1/22/1712 |
Koncentratas infuziniam tirpalui |
L01FX20 |
2023 2 21 |
||
|
2023 2 24 |
Paxlovid |
Nirmatrelviras / ritonaviras |
|
EU/1/22/1625 |
Plėvele dengta tabletė |
J05AE30 |
2023 2 27 |
— Rinkodaros leidimo pakeitimas (Europos Parlamento ir Tarybos reglamento (EB) Nr. 726/2004 13 straipsnis): Priimta
|
Sprendimo data |
Vaisto pavadinimas |
Rinkodaros leidimo turėtojas |
Įrašo numeris Bendrijos vaistų registre |
Pranešimo data |
||
|
2023 2 3 |
Ambirix |
|
EU/1/02/224 |
2023 2 6 |
||
|
2023 2 3 |
Bortezomib Hospira |
|
EU/1/16/1114 |
2023 2 6 |
||
|
2023 2 3 |
Copiktra |
|
EU/1/21/1542 |
2023 2 17 |
||
|
2023 2 3 |
Darunavir Mylan |
|
EU/1/16/1140 |
2023 2 7 |
||
|
2023 2 3 |
EVOTAZ |
|
EU/1/15/1025 |
2023 2 6 |
||
|
2023 2 3 |
Forxiga |
|
EU/1/12/795 |
2023 2 6 |
||
|
2023 2 3 |
Glivec |
|
EU/1/01/198 |
2023 2 7 |
||
|
2023 2 3 |
HALAVEN |
|
EU/1/11/678 |
2023 2 8 |
||
|
2023 2 3 |
Infanrix hexa |
|
EU/1/00/152 |
2023 2 17 |
||
|
2023 2 3 |
Invanz |
|
EU/1/02/216 |
2023 2 9 |
||
|
2023 2 3 |
KANJINTI |
|
EU/1/18/1281 |
2023 2 6 |
||
|
2023 2 3 |
Levetiracetam Accord |
|
EU/1/11/712 |
2023 2 6 |
||
|
2023 2 3 |
Nimvastid |
|
EU/1/09/525 |
2023 2 14 |
||
|
2023 2 3 |
NULIBRY |
|
EU/1/22/1684 |
2023 2 9 |
||
|
2023 2 3 |
Orencia |
|
EU/1/07/389 |
2023 2 6 |
||
|
2023 2 3 |
Pemetrexed Accord |
|
EU/1/15/1071 |
2023 2 7 |
||
|
2023 2 3 |
Quofenix |
|
EU/1/19/1393 |
2023 2 8 |
||
|
2023 2 3 |
Rasilez |
|
EU/1/07/405 |
2023 2 13 |
||
|
2023 2 3 |
Rixubis |
|
EU/1/14/970 |
2023 2 9 |
||
|
2023 2 3 |
SCENESSE |
|
EU/1/14/969 |
2023 2 7 |
||
|
2023 2 3 |
Sivextro |
|
EU/1/15/991 |
2023 2 6 |
||
|
2023 2 3 |
TRISENOX |
|
EU/1/02/204 |
2023 2 7 |
||
|
2023 2 3 |
Xagrid |
|
EU/1/04/295 |
2023 2 6 |
||
|
2023 2 3 |
Xigduo |
|
EU/1/13/900 |
2023 2 6 |
||
|
2023 2 6 |
Ebvallo |
|
EU/1/22/1700 |
2023 2 7 |
||
|
2023 2 6 |
Ebymect |
|
EU/1/15/1051 |
2023 2 7 |
||
|
2023 2 6 |
Hefiya |
|
EU/1/18/1287 |
2023 2 7 |
||
|
2023 2 6 |
Kerendia |
|
EU/1/21/1616 |
2023 2 7 |
||
|
2023 2 6 |
Tivicay |
|
EU/1/13/892 |
2023 2 7 |
||
|
2023 2 6 |
Xromi |
|
EU/1/19/1366 |
2023 2 13 |
||
|
2023 2 9 |
AMGLIDIA |
|
EU/1/18/1279 |
2023 2 14 |
||
|
2023 2 9 |
Brukinsa |
|
EU/1/21/1576 |
2023 2 10 |
||
|
2023 2 9 |
Tecentriq |
|
EU/1/17/1220 |
2023 2 13 |
||
|
2023 2 15 |
ASPAVELI |
|
EU/1/21/1595 |
2023 2 17 |
||
|
2023 2 15 |
Fulphila |
|
EU/1/18/1329 |
2023 2 16 |
||
|
2023 2 15 |
Hyrimoz |
|
EU/1/18/1286 |
2023 2 20 |
||
|
2023 2 15 |
JEMPERLI |
|
EU/1/21/1538 |
2023 2 20 |
||
|
2023 2 15 |
Lokelma |
|
EU/1/17/1173 |
2023 2 16 |
||
|
2023 2 15 |
Paxlovid |
|
EU/1/22/1625 |
2023 2 16 |
||
|
2023 2 15 |
Pemetrexed Krka |
|
EU/1/18/1283 |
2023 2 20 |
||
|
2023 2 15 |
Pregabalin Sandoz |
|
EU/1/15/1011 |
2023 3 6 |
||
|
2023 2 15 |
Semglee |
|
EU/1/18/1270 |
2023 2 16 |
||
|
2023 2 15 |
Trodelvy |
|
EU/1/21/1592 |
2023 2 16 |
||
|
2023 2 15 |
Vyndaqel |
|
EU/1/11/717 |
2023 2 16 |
||
|
2023 2 15 |
Zonegran |
|
EU/1/04/307 |
2023 2 21 |
||
|
2023 2 20 |
Aimovig |
|
EU/1/18/1293 |
2023 2 22 |
||
|
2023 2 20 |
Calquence |
|
EU/1/20/1479 |
2023 2 21 |
||
|
2023 2 20 |
Tractocile |
|
EU/1/99/124 |
2023 3 3 |
||
|
2023 2 20 |
Triumeq |
|
EU/1/14/940 |
2023 2 21 |
||
|
2023 2 20 |
Yuflyma |
|
EU/1/20/1513 |
2023 2 21 |
||
|
2023 2 23 |
Atosiban SUN |
|
EU/1/13/852 |
2023 2 27 |
||
|
2023 2 23 |
Gilenya |
|
EU/1/11/677 |
2023 2 24 |
||
|
2023 2 23 |
Ivabradine Accord |
|
EU/1/17/1190 |
2023 2 24 |
||
|
2023 2 23 |
Kinzalmono |
|
EU/1/98/091 |
2023 2 24 |
||
|
2023 2 23 |
Micardis |
|
EU/1/98/090 |
2023 3 2 |
||
|
2023 2 23 |
Nimenrix |
|
EU/1/12/767 |
2023 2 24 |
||
|
2023 2 23 |
Pemazyre |
|
EU/1/21/1535 |
2023 2 24 |
||
|
2023 2 24 |
Adcirca |
|
EU/1/08/476 |
2023 2 27 |
||
|
2023 2 24 |
Emselex |
|
EU/1/04/294 |
2023 3 1 |
||
|
2023 2 24 |
Febuxostat Mylan |
|
EU/1/17/1194 |
2023 2 27 |
||
|
2023 2 24 |
Pemazyre |
|
EU/1/21/1535 |
2023 2 27 |
||
|
2023 2 24 |
QINLOCK |
|
EU/1/21/1569 |
2023 3 3 |
||
|
2023 2 24 |
Rixathon |
|
EU/1/17/1185 |
2023 2 27 |
||
|
2023 2 24 |
Riximyo |
|
EU/1/17/1184 |
2023 2 27 |
||
|
2023 2 24 |
Ronapreve |
|
EU/1/21/1601 |
2023 2 28 |
||
|
2023 2 24 |
TUKYSA |
|
EU/1/20/1526 |
2023 3 2 |
||
|
2023 2 24 |
Wakix |
|
EU/1/15/1068 |
2023 2 27 |
||
|
2023 2 27 |
Abilify |
|
EU/1/04/276 |
2023 3 7 |
||
|
2023 2 27 |
Aflunov |
|
EU/1/10/658 |
2023 2 28 |
||
|
2023 2 27 |
Daptomycin Hospira |
|
EU/1/17/1175 |
2023 2 28 |
||
|
2023 2 27 |
Foclivia |
|
EU/1/09/577 |
2023 2 28 |
||
|
2023 2 27 |
NUBEQA |
|
EU/1/20/1432 |
2023 2 28 |
||
|
2023 2 27 |
Reblozyl |
|
EU/1/20/1452 |
2023 2 28 |
||
|
2023 2 27 |
Reblozyl |
|
EU/1/20/1452 |
2023 2 28 |
||
|
2023 2 27 |
Sprycel |
|
EU/1/06/363 |
2023 2 28 |
||
|
2023 2 27 |
Tecentriq |
|
EU/1/17/1220 |
2023 2 28 |
||
|
2023 2 27 |
Venclyxto |
|
EU/1/16/1138 |
2023 2 28 |
||
|
2023 2 27 |
Voriconazole Accord |
|
EU/1/13/835 |
2023 2 28 |
— Rinkodaros leidimo atšaukimas (Europos Parlamento ir Tarybos reglamento (EB) Nr. 726/2004 13 straipsnis)
|
Sprendimo data |
Vaisto pavadinimas |
Rinkodaros leidimo turėtojas |
Įrašo numeris Bendrijos vaistų registre |
Pranešimo data |
||
|
2023 2 23 |
Pregabalin Zentiva k.s |
|
EU/1/16/1166 |
2023 2 24 |
— Rinkodaros leidimo pakeitimas (Europos Parlamento ir Tarybos reglamento (EB) Nr. 726/2004 38 straipsnis; Europos Parlamento ir Tarybos reglamento (ES) 2019/6 5 straipsnis): Priimta
|
Sprendimo data |
Vaisto pavadinimas |
Rinkodaros leidimo turėtojas |
Įrašo numeris Bendrijos vaistų registre |
Pranešimo data |
||
|
2023 2 2 |
Tulissin |
|
EU/2/20/252 |
2023 2 6 |
||
|
2023 2 3 |
Forceris |
|
EU/2/19/235 |
2023 2 6 |
||
|
2023 2 3 |
Locatim |
|
EU/2/99/011 |
2023 2 9 |
||
|
2023 2 3 |
Panacur AquaSol |
|
EU/2/11/135 |
2023 2 7 |
||
|
2023 2 6 |
Apoquel |
|
EU/2/13/154 |
2023 2 7 |
||
|
2023 2 6 |
CLYNAV |
|
EU/2/16/197 |
2023 2 7 |
||
|
2023 2 6 |
Procox |
|
EU/2/11/123 |
2023 2 8 |
||
|
2023 2 6 |
Procox |
|
EU/2/11/123 |
2023 2 7 |
||
|
2023 2 6 |
Versican Plus DHPPi/L4R |
|
EU/2/14/163 |
2023 2 7 |
||
|
2023 2 9 |
MiPet Easecto |
|
EU/2/17/220 |
2023 2 14 |
||
|
2023 2 20 |
Advocate |
|
EU/2/03/039 |
2023 2 22 |
||
|
2023 2 20 |
Bovela |
|
EU/2/14/176 |
2023 2 22 |
||
|
2023 2 20 |
GALLIPRANT |
|
EU/2/17/221 |
2023 2 21 |
||
|
2023 2 20 |
Suvaxyn Circo + MH RTU |
|
EU/2/15/190 |
2023 2 23 |
||
|
2023 2 23 |
Locatim |
|
EU/2/99/011 |
2023 3 1 |
Norintieji susipažinti su nagrinėjamųjų vaistų vieša vertinimo ataskaita ir su ja susijusiais sprendimais, gali kreiptis į:
|
European Medicines Agency |
|
Domenico Scarlattilaan 6 |
|
1083 HS Amsterdam |
|
NETHERLANDS |